QIAGEN OmicSoft and Biomedical Knowledge Base

Exploring drug response in low-grade glioma

August 31, 2022
See how Dr, Nilson from QIAGEN Digital Insights navigates an interesting intersection of the tumor microenvironment, mutation status, and gene expression to identify plausible activators affecting bevacizumab targets in low-grade glioma.

In this webinar participants will learn about
  • The tools used to identify key genes in LGG
  • How we choose specific gene alterations
  • The intersection between immune response tumor mutations
  • How we identify other key genes of interest 
  • How we build a network tying all these elements together

Related videos

QIAGEN OmicSoft and Biomedical Knowledge Base

Checkpoint inhibitors investigation in context of biomarkers, drug targets and pathways using...

278 views September 15, 2022

This training will focus on how QIAGEN Omicsoft Studio and IPA can be used to...


Systems analysis of cancer cell lines for drug target discovery

435 views April 25, 2022

Cancer cell line models have been a cornerstone of cancer research for...

QIAGEN OmicSoft and Biomedical Knowledge Base

Public single-cell RNA-seq data investigation using QIAGEN OmicSoft and Ingenuity Pathway Analysis

69 views February 29, 2024

Single-cell RNA-sequencing (scRNA-seq) is widely used to investigate tissue...